SLC38A2 and breast carcinoma: Recently, increased glutamine uptake by the SLC38A2 (SNAT2) amino acid transporter has been demonstrated to drive hypoxia-mediated resistance to endocrine therapy.94 Inhibiting SNAT2 expression sensitised breast cancer cells to anti-oestrogen treatment.